Private company

Opexa Therapeutics

American pharmaceutical preparations company based in Houston.¹

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersHouston¹
Websitewww.opexatherapeutics.com
Legal formFor-Profit Corporation¹
Listed onNasdaq¹
Incorporated inDE³
Business addressOne Gateway Center (300 Washington St.), Suite 356, Newton, Ma 02458³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-1265.7%Operating margin⁴

-1220.2%Net margin⁴

-$189.9KFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2021

Research and development

Research and development100¢$6.5M

Out of $1.3M in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁴$1.3M in 2021

Operating income⁶⁷⁸⁹⁵⁴-$15.9M in 2021+138% since 2016

Net income⁶⁷⁸⁹⁵⁴-$15.4M in 2021+129% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021
Revenue					$0⁵	$1.3M⁴
Research and development	$5.3M⁶	$8.7M⁷	$12.5M⁸	$13.9M⁹	$11.8M⁵	$6.5M⁴
Operating income	-$6.7M⁶	-$13.9M⁷	-$21.7M⁸	-$29.9M⁹	-$22.8M⁵	-$15.9M⁴
Interest
Income tax	$0⁶	$0⁷	$0⁸	$0⁹	$0⁵	$0⁴
Net income	-$6.7M⁶	-$14.2M⁷	-$21.3M⁸	-$29.4M⁹	-$22.9M⁵	-$15.4M⁴
Earnings per share						-$1.08⁴
Earnings per share (diluted)						-$1.08⁴

Total assets⁶⁷⁸⁹⁵⁴$36.3M in 2021+1207% since 2016

Total liabilities⁶⁷⁸⁹⁵⁴$38.0M in 2021+4524% since 2016

Shareholders’ equity⁷⁸⁹⁵⁴-$1.7M in 2021−83% since 2016

Cash⁷⁸⁹⁵⁴$12.7M in 2021+593% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021
Cash	$1.8M⁷	$15.6M⁷	$41.7M⁸	$12.1M⁹	$5.8M⁵	$12.7M⁴
Current assets	$2.4M⁶	$16.5M⁷	$42.7M⁸	$12.9M⁹	$6.4M⁵	$28.1M⁴
Total assets	$2.8M⁶	$24.4M⁷	$50.7M⁸	$21.5M⁹	$14.6M⁵	$36.3M⁴
Current liabilities	$1.2M¹²		$5.6M⁸	$2.8M⁹	$6.1M⁵	$29.1M⁴
Total liabilities	$821.4K⁶	$2.0M⁷	$5.6M⁸	$3.1M⁹	$6.4M⁵	$38.0M⁴
Shareholders’ equity	-$10.2M⁷	$22.3M⁸	$45.1M⁹	$18.4M⁵	$8.2M⁴	-$1.7M⁴
Shares outstanding	2.5M shares⁶	7.5M shares⁷	10.1M shares⁸	10.1M shares⁹	13.2M shares⁵	14.3M shares⁴

Cash from operations⁷⁸⁹⁵⁴-$134.9K in 2021−99% since 2017

Capital spending⁶⁷⁸⁹⁵⁴$54.9K in 2021+3373% since 2016

Free cash flow⁷⁸⁹⁵⁴-$189.9K in 2021−99% since 2017

Fiscal year	2016	2017	2018	2019	2020	2021
Cash from operations		-$14.1M⁷	-$16.6M⁸	-$29.5M⁹	-$17.0M⁵	-$134.9K⁴
Capital spending	$1.6K⁶	$62.8K⁷	$95.6K⁸	$179.0K⁹	$10.9K⁵	$54.9K⁴
Free cash flow		-$14.2M	-$16.7M	-$29.7M	-$17.0M	-$189.9K

Compare Opexa Therapeutics with another company

Leadership

Who has led Opexa Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Tanya Hayden2022–2023

2010201520202025

Chief executive officerChris Schelling Sep 21, 2017 to Nov 20, 2023¹³
Chief executive officerNeil K. Warma Jun 19, 2008 to May 18, 2016¹⁴
Chief executive officerDavid McWilliams Jun 19, 2006 to May 8, 2008¹⁵
PresidentChris Schelling Sep 21, 2017 to Nov 20, 2023¹³
PresidentNeil K. Warma Jun 19, 2008 to May 18, 2016¹⁴
Chief financial officerHarry S. Palmin Sep 21, 2017 to Nov 20, 2023¹⁶
Chief financial officerNeil K. Warma May 18, 2016 to May 18, 2016¹⁷
Chief financial officerKarthik Radhakrishnan Apr 1, 2013 to Apr 9, 2015¹⁸
Chief financial officerDavid Emerson Jorden Aug 16, 2012 to Feb 27, 2013¹⁹
Chief financial officerWilliam Rouse Apr 27, 2006 to Jun 19, 2006²⁰
Chief financial officerDavid McWilliams Apr 28, 2006 to Apr 28, 2006²¹
Chief financial officerLynne Hohlfeld Jul 6, 2006 to Jan 20, 2009²²
Chief operating officerTanya Hayden Jun 22, 2022 to Mar 16, 2023²³

Board members and other officers (30)

OfficerDonald Joseph Nov 20, 2023 to Nov 20, 2023²⁴
Chief People OfficerBernard H. Paul Jan 21, 2022 to Mar 16, 2023²⁵
Chief Medical OfficerAdrian W. Quartel Feb 23, 2022 to Mar 16, 2023²⁶
Chief Business OfficerJefferson E. Davis Feb 5, 2021 to Nov 20, 2023²⁷
Chief Opp. and Financial OffrHarry S. Palmin Feb 5, 2019 to Jan 19, 2022²⁸
Chief Commercial OfficerMatthew Seibt Sep 23, 2019 to Jan 19, 2022²⁹
Chief Technology OfficerJohn Michael Klopp Sep 25, 2019 to Mar 16, 2023³⁰
Chief Commercial OfficerSalma Jutt-Eghbali Dec 6, 2018 to Dec 6, 2018³¹
Chief Medical OfficerRobert D. Steiner Sep 21, 2017 to Sep 21, 2017³²
Vice President, OperationsDonna R. Rill Apr 2, 2007 to May 18, 2016³³
Board memberChris Schelling Sep 21, 2017 to Nov 20, 2023¹³
Board memberJason Amello Sep 21, 2017 to Mar 16, 2023³⁴
Board memberMichelle Burris Sep 21, 2017 to Mar 16, 2023³⁵
Board memberSteve Aselage Sep 21, 2017 to Nov 20, 2023³⁶
Board memberHubert Birner Sep 27, 2017 to Aug 22, 2018³⁷
Board memberLuc Marengere Sep 27, 2017 to Aug 22, 2018³⁸
Board memberHans-Peter Hartung Mar 21, 2014 to Apr 1, 2015³⁹
Board memberTimothy C. Barabe Mar 21, 2014 to Nov 22, 2016⁴⁰
Board memberGail J. Maderis Oct 28, 2011 to Oct 4, 2016⁴¹
Board memberNeil K. Warma Apr 16, 2009 to May 18, 2016⁴²
Board memberDavid Emerson Jorden Aug 13, 2008 to Sep 26, 2013⁴³
Board memberLorin Randall Sep 21, 2007 to Jun 30, 2008⁴⁴
Board memberTerry Wesner Feb 10, 2006 to Feb 10, 2006⁴⁵
Board memberGregory Bailey Apr 24, 2006 to Jun 30, 2008⁴⁶
Board memberScott B. Seaman Apr 24, 2006 to Oct 4, 2016⁴⁷
Board memberDavid McWilliams Apr 28, 2006 to Aug 27, 2009²¹
Board memberPaul Frison May 9, 2006 to Jun 19, 2006⁴⁸
Board memberDavid Hung May 25, 2006 to Apr 7, 2011⁴⁹
Board memberMichael Richman Jun 22, 2006 to Oct 4, 2016⁵⁰
General counselDonald Joseph Apr 23, 2018 to Mar 16, 2023⁵¹

Former names

Opexa Therapeutics, Inc.Jun 16, 2006 to Sep 20, 2017³
PharmaFrontiers Corp.Oct 11, 2005 to Jun 2, 2006³
PHARMAFRONTIERS CORPAug 16, 2004 to Oct 5, 2005³
SPORTAN UNITED INDUSTRIES INCJul 2, 1999 to Jul 1, 2004³

Timeline

Sep 21, 2017New chief executive Chris Schelling becomes CEO¹³
Dec 26, 2013Founded Opexa Therapeutics is founded⁵²
Jun 19, 2008New chief executive Neil K. Warma becomes CEO¹⁴
Jun 19, 2006New chief executive David McWilliams becomes CEO¹⁵

Filings

172 filings to the SEC since October 2021: 2 annual reports, 10 quarterly reports, 70 major events, 36 insider forms, 4 large holders, 1 private raises, 49 other. The latest 20:

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 4 such filings since October 2021:

Mar 30, 2023SC 13D/A
Feb 14, 2023SC 13G/A
Dec 2, 2022SC 13D/A
Feb 14, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Nov 29, 2022Raised $1.5 million in a private offering of equity Form D: 2 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataOpexa Therapeutics on Wikidata
2
SEC EDGAROpexa Therapeutics filings on SEC EDGAR
3
SEC EDGAROpexa Therapeutics filings on SEC EDGAR
4
SEC EDGAROpexa Therapeutics 10-K for fiscal 2021
5
SEC EDGAROpexa Therapeutics 10-K for fiscal 2020
6
SEC EDGAROpexa Therapeutics 10-K for fiscal 2016
7
SEC EDGAROpexa Therapeutics 10-K for fiscal 2017
8
SEC EDGAROpexa Therapeutics 10-K for fiscal 2018
9
SEC EDGAROpexa Therapeutics 10-K for fiscal 2019
10
SEC EDGAROpexa Therapeutics 10-Q for fiscal 2023
11
SEC EDGAROpexa Therapeutics 10-Q for fiscal 2023
12
SEC EDGAROpexa Therapeutics 10-K for fiscal 2016
13
SEC EDGARChris Schelling, Chief executive officer
14
SEC EDGARNeil K. Warma, Chief executive officer
15
SEC EDGARDavid McWilliams, Chief executive officer
16
SEC EDGARHarry S. Palmin, Chief financial officer
17
SEC EDGARNeil K. Warma, Chief financial officer
18
SEC EDGARKarthik Radhakrishnan, Chief financial officer
19
SEC EDGARDavid Emerson Jorden, Chief financial officer
20
SEC EDGARWilliam Rouse, Chief financial officer
21
SEC EDGARDavid McWilliams, Chief financial officer
22
SEC EDGARLynne Hohlfeld, Chief financial officer
23
SEC EDGARTanya Hayden, Chief operating officer
24
SEC EDGARDonald Joseph, Officer
25
SEC EDGARBernard H. Paul, Chief People Officer
26
SEC EDGARAdrian W. Quartel, Chief Medical Officer
27
SEC EDGARJefferson E. Davis, Chief Business Officer
28
SEC EDGARHarry S. Palmin, Chief Opp. and Financial Offr
29
SEC EDGARMatthew Seibt, Chief Commercial Officer
30
SEC EDGARJohn Michael Klopp, Chief Technology Officer
31
SEC EDGARSalma Jutt-Eghbali, Chief Commercial Officer
32
SEC EDGARRobert D. Steiner, Chief Medical Officer
33
SEC EDGARDonna R. Rill, Vice President, Operations
34
SEC EDGARJason Amello, Board member
35
SEC EDGARMichelle Burris, Board member
36
SEC EDGARSteve Aselage, Board member
37
SEC EDGARHubert Birner, Board member
38
SEC EDGARLuc Marengere, Board member
39
SEC EDGARHans-Peter Hartung, Board member
40
SEC EDGARTimothy C. Barabe, Board member
41
SEC EDGARGail J. Maderis, Board member
42
SEC EDGARNeil K. Warma, Board member
43
SEC EDGARDavid Emerson Jorden, Board member
44
SEC EDGARLorin Randall, Board member
45
SEC EDGARTerry Wesner, Board member
46
SEC EDGARGregory Bailey, Board member
47
SEC EDGARScott B. Seaman, Board member
48
SEC EDGARPaul Frison, Board member
49
SEC EDGARDavid Hung, Board member
50
SEC EDGARMichael Richman, Board member
51
SEC EDGARDonald Joseph, General counsel
52
gleifOpexa Therapeutics is founded